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Abstract 
 Atherosclerosis, as a potentially serious condition, has become one of 
the most prevalent causes of mortality over the world. RAS (Renin-
angiotensin-system) is recognized to be a key role in the development of 
atherosclerosis, which considered as a chronic inflammatory disease. Ang II 
(angiotensin II) is proven to cause atherosclerosis, hypertension and aortic 
aneurysms. While activation of Mas receptors by Ang-(1-7) [angiotensin-(1-
7)] shows an important role in prevention of atherosclerosis. The activation 
of Ang-(1-7)/Mas receptor axis counteracts Ang II-induced hypertension, 
inflammation, fibrosis and apoptosis responses. We have concluded that, the 
relationship between Ang-(1-7)/Mas axis and vascular inflammation could be 
the paving-stone of the avoidance and novel treatment for atherosclerosis. 
The scope of this study is to review the relationship between Ang-(1-7)/Mas 
axis and vascular inflammation in the development of atherosclerosis. 
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Atherosclerosis 
 Atherosclerosis, as vascular disease is observed commonly in 
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patients, is a potentially serious condition which has become one of the most 
prevalent causes of mortality in developed and developing countries (Leong, 
Ng, & Jaarin, 2015). More than 50% of the cause of deaths is related to 
atherosclerosis in the USA, Europe and Japan (Ross, 1993). Atherosclerosis 
is an insidious disease, which exists in humans for a long-term without any 
symptom. Nevertheless, it is usually accompanied by ischemia, angina, 
myocardial infarction, stroke and cardiac failure (Husain, Hernandez, Ansari, 
& Ferder, 2015; Moss & Jaffe, 2015). All these are global health challenges 
in recent years. 
 Dozens of years ago, atherosclerosis used to be considered as a 
chronic disease caused by the accumulation of cholesterol and thrombotic 
debris in the artery wall (Libby, 2012). In the 1970s, researchers suggested 
that the proliferation of smooth muscle cells is the nidus of atherosclerotic 
lesion plaques (Ross & Glomset, 1976a, 1976b). However, in recent decades, 
more and more experiments demonstrated that atherosclerosis is a chronic 
inflammatory process caused by the cardiovascular risk factors and the 
vascular remodeling (Libby, 2012). The storage of fatty substances, 
cholesterol, connective tissue, thrombus, calcium and fibrin is the main 
reason for the formation of atherosclerotic plaques inside the arteries. This 
leads to the thickening of the arterial wall and narrowing of the arteries. And 
finally, it causes the arteries sclerosis and elastic loss (Finn, Nakano, Narula, 
Kolodgie, & Virmani, 2010). In general, the increasing accumulation of 
adipocytes can augment the release of free fatty acid, enhance the 
physiological stress and promote the generation of ROS (reactive oxygen 
species). These stress factors can induce the release of inflammatory 
adipokines, such as IL-6 (interleukin- 6), Serum amyloid A and MCP-1 
(monocyte chemotactic protein 1). Then the inflammatory adipokines enter 
the circulation, promote the activated monocytes differentiate into the arterial 
wall and adipose tissue. Also, the monocytes can differentiate into 
macrophages, which can release cytokines. The released cytokines also 
promote the inflammatory process (Gustafson, 2010). Apart from aorta, and 
the cardiac coronary artery, cerebral artery and renal artery are the main 
formative parts of atherosclerosis. It may lead to aneurysm rupture, 
thrombosis and stenosis to occlusion, which show disorders of blood supply 
in some organs. The pathological process of atherosclerosis is complex, and 
the influencing factors are multifaceted. 
 ACE2/Ang-(1-7)/Mas axis was found to play a vital role in the 
treatment of atherosclerosis (McKinney, Fattah, Loughrey, Milligan, & 
Nicklin, 2014). Most of the experiments show evidences that activated Ang-
(1-7)/Mas axis attenuates the inflammatory process. Accordingly, it makes 
sense to study the ACE2/Ang-(1-7)/Mas axis to better understand the 
prevention mechanism of atherosclerosis. Meanwhile, this could provide new 
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ideas for the prevention and treatment of atherosclerotic vascular disease. 
Thus, we focus on the recent discovery of Ang-(1-7)/Mas axis and vascular 
inflammation, as well as its future prospects. 
 
Renin-Angiotensin System  
 As a major human health challenge, atherosclerosis attracts 
increasing attention from the researchers. Pathological processes, preventive 
strategies and therapeutic methods come to light progressively. RAS (Renin-
angiotensin system) plays a central role in the pathogenesis of cardiovascular 
disease, including atherosclerosis, AAA (abdominal aortic aneurysm) and 
hypertension (Ferrario & Strawn, 2006; Guang, He, Yu, & Yao, 2015; Husain 
et al., 2015). There are two main axes in the research of RAS：ACE/Ang 
II/AT1R axis and ACE2/Ang-(1-7)/Mas axis. Activation of ACE/Ang 
II/AT1R axis aggravates the development of atherosclerosis. In opposite, 
activation of ACE2/Ang-(1-7)/Mas axis improves the Ang II-induced effects 
in atherosclerosis. 
 
Angiotensin II 
 Ang II is an important peptide in RAS, can induce endothelial 
dysfunction, hypertension, inflammation, atherosclerosis and cardiac 
hypertrophy (Weiss, Kools, & Taylor, 2001). Ang II degraded from Ang I 
(angiotensin I) through the enzymatic degradation of ACE (angiotensin-
converting enzyme). And then, Ang II activates AT1R (Angiotensin II Type I 
Receptors) and AT2R (Angiotensin II Type II Receptors) to regulate the 
physiological effects (Savoia, Burger, Nishigaki, Montezano, & Touyz, 
2011). Daugherty et al. first found that Ang II accelerated the development of 
atherosclerosis and AAA in ApoE knockout (ApoE-KO) mice in 2000 
(Daugherty, Manning, & Cassis, 2000). Macrophage in filtration, T cell 
infiltration and B cell infiltration was observed in the vascular wall. This 
plays a central role in vascular inflammation. Besides, Ang II is involved in 
the development of atherosclerosis via stimulating the proliferation of 
VSMC (vascular smooth muscle cells), and it also induces associated 
symptoms via hypertension. Since increasing pressure of the vascular wall is 
considered to be a pro-inflammatory stimuli (Taylor, 1998). In addition, it 
causes fibrosis, vasoconstriction and angiosteosis through disrupting the 
growth and apoptosis of VSMC (Savoia et al., 2011; Simoes e Silva, 
Silveira, Ferreira, & Teixeira, 2013). ROS and peroxide production are 
highly related to the procedure (Mehta & Griendling, 2007). Additionally, 
over-expression of inflammatory factors have also been approved in this 
process (Xie, Sun, Yang, & Sun, 2006). Ultimately, development of AAA and 
atherosclerosis is independent of hypercholesterolemia and high blood 
pressure (Cassis et al., 2009). This was confirmed in clinical researches and 
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animal experiments. 
 
Angiotensin-(1-7) and Mas receptor 
 Ang-(1-7) is the endogenous ligand for G-protein-coupled Mas 
receptors (Gironacci et al., 2011; Kostenis et al., 2005). It is confirmed that 
Ang-(1-7) plays a prevention role in RAS, and it also shows many effects in 
related physiology and pathology (Stegbauer, Vonend, Oberhauser, & Rump, 
2003). Ang-(1-7) is degraded from Ang II by PEP (prolyl endopeptidase), 
PCP (prolyl carboxypeptidase) or ACE2. Also, after the hydrolysis by PEP or 
EP (endopeptidase), Ang I can be degraded into Ang-(1-7). Or Ang I can be 
degraded into Ang-(1-9) primarily by ACE1, and then Ang-(1-9) will be 
degraded into Ang-(1-7) by ACE or EP (Savoia et al., 2011). Especially, Ang 
II (protein sequences: NH2-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) is degraded 
into Ang-(1-7) (protein sequences: NH2-Asp-Arg-Val-Tyr-Ile-His-Pro) by 
ACE2 is considered to be the main pathway. 
 Mas receptor, encoded from MAS1 oncogene, is a G protein-coupled 
receptor which activated by Ang-(1-7), the metabolite of Ang II. What’s 
more, Mas receptor is a seven transmembrane receptor (Young, Waitches, 
Birchmeier, Fasano, & Wigler, 1986). It is widely expressed in brain, but 
little in heart, liver, lung, kidney, spleen and skeletal muscle (Metzger et al., 
1995). The human Mas receptor is composed of 325 amino acid residues, 
meanwhile, the Mas receptor from rat and mouse is composed of 324 amino 
acid residues. Furthermore, Mas receptors are highly conserved. For 
example, the encoded protein homology is 97% between rat and mouse, and 
91% between human and mouse (Metzger et al., 1995). 
 Activated ACE2/Ang-(1-7)/Mas axis shows an antagonism effect to 
activated ACE/Ang II/AT1R axis. Therefore, Mas receptors’ agonists and 
Ang II receptors’ antagonists show the same treatment effect in hypertension 
(Santos & Ferreira, 2006). Since Ang-(1-7) can suppress the migration of 
leukocytes, expression of cytokines and fibrosis in inflammatory response 
(Simoes e Silva et al., 2013). It inhibited early atherosclerotic lesions via 
protecting the endothelial cells, and suppressing the proliferation and 
migration of smooth muscle cells. Ang-(1-7) enhanced plaque stability 
through attenuates the inflammatory response and MMP’s expression and 
activities (Masson et al., 2009). Potthoff et al. shown that, Ang-(1-7) actives 
the Mas receptors to mediate the vascular function that attenuates pressor 
response to Ang II in ApoE-KO mice by reducing ROS-mediated p38 MAPK 
(mitogen-activated protein kinase) activity (Potthoff et al., 2014). Rodrigo A. 
Fraga-Silva (Fraga-Silva et al., 2014) observed that, compare to the 
oscillatory shear stress-induced plaque, Ang-(1-7) increased intra-plaque 
collagen content in aortic root region, reduced shear stress-
induced carotid plaques, decreased MMP-9 content, and declined neutrophil 
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and macrophage infiltration in ApoE-KO mice treated with Western-type 
diet. And in vitro incubation with Ang-(1-7) did not influence the expression 
and apoptosis of ICAM-1 in cultured endothelial cells.  Furthermore, many 
experiments demonstrated that deletion of ACE2 gene in ApoE-KO mice 
leads to the decrease of Ang-(1-7). In the meantime, vascular cell adhesion 
molecules (VCAM), cytokines, chemokines and matrix metalloprotease 
(MMP) are increased. This aggravates the vascular inflammation and 
atherosclerosis (Thomas et al., 2010). But over expression of ACE2 severe 
cardiac fibrosis, which adverse response to the organism (Masson et al., 
2009). Extensive researches have shown that, Ang-(1-7) dose-dependently 
ameliorates atherosclerosis (Yang et al., 2013). In contrast, Ang-(1-7) caused 
the pathological outcome by aggravating the inflammatory response, because 
Mas receptor deficiency depressed NF-κB activation (Esteban et al., 2009). 
And this is independently from Ang II receptors. Consequently, treatment 
with an oral formulation of Ang-(1-7) can reduce inflammation and enhance 
a more stable phenotype in carotid atherosclerotic plaques. In summary, Mas 
receptors as an essential part of RAS are important for future researches in 
cardiovascular therapeutics and the drug development. 
 
Figure 1 
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 The RAS is a central regulation system in the development of 
atherosclerosis. The main effector peptides are mainly generated by the 
actions of ACE and ACE2. Activated ACE/Ang II/AT1R axis increases ROS 
production, decreases eNOS, and causes hypertension, endothelial 
dysfunction, tissue inflammation, fibrosis, cell apoptosis, cardiac 
hypertrophy and VSMC proliferation and migration. While, activated 
ACE2/Ang-(1-7)/Mas axis decreases oxidative stress, inflammation and 
fibrosis levels, increases NO bioavailability, and causes vasodilation and 
angiogenesis. It also reduces collagen synthesis, MMP-2 and MMP-9 
expression levels. All of these cases are related to the development of 
atherosclerosis and vascular remodeling. ACE, angiotensin converting 
enzyme; PEP, prolyl-endopeptidase; NEP, neutral endopeptidase; PCP, 
prolyl-carboxypeptidase.  
 
Atherosclerosis and Vascular Inflammation 
 Atherosclerosis leads to the vascular endothelial cells dysfunction, 
influences the migration, proliferation and apoptosis of vascular smooth 
muscle cells. Also it promotes the differentiation of monocytes, 
accumulation of macrophages and release of cytokines. Furthermore, 
atherosclerosis causes the vascular remodeling, and influences the synthesis 
and degradation processes of extracellular matrix. Nonetheless, the 
mechanism relationship between adventitia and ACE2/Ang-(1-7)/Mas axis 
remains unclear. 
 
Macrophage 
 Macrophage, is a type of white blood cell in a process called 
phagocytosis, derived from monocytes differentiation. Both macrophages 
and monocytes are phagocytes. They are involved in innate immune cells 
and immune process. Beyond increasing inflammation and stimulating the 
immune system, macrophages also play a vital important anti-inflammatory 
role and can release cytokines to decrease the immune reaction. In some 
metabolic diseases situations, such as hyperlipoidemia, hypertension and 
diabetes mellitus, macrophages will be activated. And then macrophages 
keep in influencing vessels during the period from the early atherosclerotic 
arterial phase to clinical complications stage (Libby, 2012). Hyperlipemia 
can increase monocytes through encouraging the pro-inflammatory cytokines 
release from peripheral blood monocytes. Afterwards, monocytes invasive 
into the sub-endothelium space and differentiate into macrophages through 
the adhesion molecules (Koga & Aikawa, 2012). This process is called 
macrophage infiltration. Significant invasion of macrophages is the 
characteristic of vulnerable plaque (Yang et al., 2013). And then, the oxLDL 
will store in the macrophages to form foam cells. Activated macrophages 
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will release varies inflammatory factors and adhesion molecules, such as 
MCP-1 that further exacerbate the increase of macrophages. Thus, 
macrophages are considered as an important factor in the formation of 
atherosclerotic plaques. As a matter of fact, macrophages play a key role in 
atherosclerosis throughout the pathological processes. Meanwhile, Ang-(1-7) 
reduces the development of atherosclerosis through attenuating the 
inflammatory response caused by macrophages (Souza & Costa-Neto, 2012). 
 Ang-(1-7) reduced the macrophages level in coronary plaques and 
enhanced the plaque stability (Yang et al., 2013). Larura (Souza & Costa-
Neto, 2012) found that, Ang-(1-7) decreased LPS induced inflammatory 
response induced in macrophages. The expression of TNF-α and IL-6 has 
been suppressed. But the inhibition of pro-inflammatory cytokines was not 
observed under the activation of A779, the antagonist of Mas receptors. 
Interleukin-6 (IL-6), as an inflammatory marker of local coronary plaque and 
blood circulation, can aggravate the development of atherosclerosis and even 
cause aneurysms rupture (Wang, Liu, Wang, & Jin, 2014). Tumor necrosis 
factor alpha (TNF-α) is a cytokine involved in systemic inflammation, and it 
was mainly secreted by monocytes and macrophages. It mediates cell 
survival, proliferation and apoptosis (Ma et al., 2014). Ang-(1-7) decreased 
the phosphorylation level of Lyn in this process (Souza & Costa-Neto, 2012). 
Consequently, Ang-(1-7) has anti-inflammatory role via mediating the Src 
kinases activities to decrease the expression of pro-inflammatory cytokines.  
 Macrophages have different subpopulations. Atherosclerotic lesion 
plaques are mainly contained two subpopulations, pro-inflammatory 
macrophages (M1) and anti-inflammatory macrophages (M2). The excessive 
ratio of M1/M2 will lead to lesion formation and plaque vulnerability in the 
lesion area (Koga & Aikawa, 2012). Ang-(1-7) can reduce the ratio of 
M1/M2. It was also found that the M2 related genes Arg-1 and CCL9 were 
positive regulated, and the M1 related genes CD86 and iNOS (inducible 
nitric oxide synthase) was negative regulated. At the same time, the 
expression of TNF-α, IL-6 and MCP-1 was obviously decreased (Yang et al., 
2013). Additionally, MMPs are produced by a range of cells including 
macrophages and VSMC (Ng, Morris, & Golledge, 2015). MMP-2 and 
MMP-9 have been suggested playing an important role in vascular 
remodeling through extracellular matrix degradation. Ang-(1-7) caused the 
noticeable reduction of pro-MMP-2、MMP-2、pro-MMP-9、MMP-9 in 
aortic plaques. However, Ang II increased the mRNA expression of MMP-
2、MMP-9 in macrophages. As a consequence, Ang-(1-7) can attenuate the 
inflammatory responses in plaques and the expression of inflammatory 
cytokines in macrophages. 
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Vascular Endothelial Cells 
 Vascular endothelium is the inner part of the vessel, and is involved 
in endocrine and paracrine to regulate the vascular wall function. Endothelial 
dysfunction is considered to be the initial process of atherosclerosis (Onat, 
Brillon, Colombo, & Schmidt, 2011). At the same time, vascular 
endothelium is one part about the production and action of Ang-(1-7) 
(Verano-Braga et al., 2012). Many inflammatory factors seem to be related to 
this process. Many experimental results showed that, Ang-(1-7) decreased 
the migration of white blood cells, expression of chemokines and fibrosis. 
ACE2 deficiency augmented monocytes adhesion and inflammatory factors 
release to endothelial cells in mice (Z. Zhang, Chen, Zhong, Gao, & Oudit, 
2014). As a consequence, vascular dysfunction is considered as a key factor 
during the whole development of atherosclerosis. The research of vascular 
endothelial cells and its related risk factors has a positive meaning in the 
understanding of pathological process of atherosclerosis. 
 Stegbauer (Stegbauer et al., 2011) found that, Ang-(1-7) attenuated 
the renal vascular dysfunction in ApoE-KO mice with Western-type diet. The 
possible reason is that Ang-(1-7) mediated NO (nitric oxide) production so 
that increased the bioavailability of NO. This may be caused by the 
activation of Mas receptors through Ang-(1-7). In summary, Ang-(1-7)/Mas 
pathway modulates vascular function, and the activated Mas receptor 
attenuates pressor response to Ang II in ApoE-KO mice by reducing reactive 
oxygen species-mediated p38 mitogen-activated protein kinase activity 
(Potthoff et al., 2014). Thiago (Verano-Braga et al., 2012) studied the human 
aortic endothelial cells treated with Ang-(1-7). The results suggest that the 
anti-proliferative activity of Ang-(1-7) is owing to the activation or 
inactivation of several target phosphoproteins, such as FOXO1 (fork head 
box protein O1), mitogen-activated protein kinase 1 and AKT1S1 (proline-
rich AKT1 substrate 1). Zhang (F. Zhang, Ren, Chan, & Chen, 2013) found 
that, Ang-(1-7) attenuates the inflammatory process via Mas-receptor 
activation that reducing the expression of VCAM-1 and NF-kappaB in the 
vascular endothelial cells. The AT1 receptor antagonist can increase the 
expression of ACE2/Ang-(1-7)/Mas axis, thereby, reducing the expression of 
pro-inflammatory factors TNF-α, IFN-γ, IL-1β and IL-6. And it also induces 
the expression of anti-inflammatory factors, such as IL-10 (Simoes e Silva et 
al., 2013). Thus, Ang-(1-7)/Mas pathway plays an active role in the 
maintenance of endothelial function and inflammatory process. 
 Vascular cell adhesion molecule 1 (VCAM-1) also known as vascular 
cell adhesion protein 1 or cluster of differentiation 106 (CD106), which is 
encoded by the VCAM1 gene in human body (Cybulsky et al., 1991). 
VCAM-1 stimulates lymphocytes, monocytes, eosinophils and basophils 
adhere to the vascular endothelium. It involves the cell identification, cell 
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activation and signal transduction, also mediates the stretching, movement, 
growth and differentiation of the cells. Experimental results suggest that 
VCAM-1 mainly stimulates monocytes adhere to vascular endothelium in 
early disease process period of atherosclerosis. Moreover, the adhesion of T-
lymphocytes and monocytes to vascular endothelial cells means the 
beginning of atherosclerosis inflammation. Consequently, VCAM-1 is 
considered playing an important role in the physiological and pathological 
processes of inflammation, thrombosis and atherosclerosis. 
 In the research of vascular endothelium, Ang II enhanced the mRNA 
expression of VCAM-1 (F. Zhang et al., 2013). But there was no effect when 
EC were only treated with Ang-(1-7). However, Ang-(1-7) significantly 
suppressed the gene expression of VCAM-1 when EC treated together with 
Ang II and Ang-(1-7), and it also decreased the promoter activity of VCAM-
1. At the same time, the translocation of NF-kappaB is also reduced. At the 
same time, when EC were treated with Ang II, Ang-(1-7) and A-779 together, 
the inhibition of VCAM-1 promoter and translocation of NF-kappaB were 
not observed. Thus, Ang-(1-7) is an integral part of the RAS, can regulate 
ECs though Mas receptors, also suppress the expression of VCAM-1 
activated by Ang II via decreasing the translocation of NF-kappaB. 
 
Vascular Smooth Muscle Cells 
 Vascular smooth muscle cells (VSMC）is one of the main 
components of the vascular wall, can cause the change of blood pressure. 
Excessive vasoconstriction can increase blood pressure. Conversely, 
excessive vasodilation can decrease the blood pressure. The proliferation and 
migration of VSMC are considered to be one of the early features of 
atherosclerosis (Yang et al., 2013). VSMC is related to a variety of 
mechanisms of vascular disease. In addition, the activated VSMC in 
atherosclerotic lesion parts can produce diversity of cytokines and proteases 
(Koga & Aikawa, 2012). In the lesion area with inflammation, MMPs are 
over expressed by macrophages. And in the fibrous cap, VSMC will produce 
excess collagen-degrading enzymes. The terrible result is the rupture of the 
lesion plaque because of the thinner vascular. Moreover, Ang II is not only 
shown regulations in cardiovascular and renal steady, but also showed 
functions in cardiovascular disease, atherosclerosis, hypertension and cardiac 
failure. Activation of MAPKs by Ang II can cause the migration, 
proliferation and inflammation of VSMC (Eguchi, Dempsey, Frank, Motley, 
& Inagami, 2001; Rateri et al., 2014). At the same time, the activation of 
Ang-(1-7)/Mas shows an antagonist function to it. Thus, the inflammatory 
mechanism research of VSMC is a key point for the therapy of 
atherosclerosis and aortic aneurysm. 
 Yang (Yang et al., 2013) found that, Ang II increased the proliferation 
European Scientific Journal November 2015 edition vol.11, No.33 ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
10 
and migration of VSMC, and it also increased the phosphorylation level of 
ERK/P38 and JAK/STAT, promoted the mRNA expression of MMP-2 and 
MMP-9. But all the conditions were normal when co-infusion with Ang II 
and Ang-(1-7) together. This means that, Ang-(1-7) offset the adverse effects 
of Ang II to VSMC. The qPCR results show that, Ang-(1-7) increased the 
mRNA level of AT2R, but nothing observed in the mRNA level of AT1R and 
Mas. Ang-(1-7) adjusted the composition of coronary plaques and increased 
the VSMC collagen content. Thereby enhanced the stability of the plaques. 
SM22 α is a cytoskeletal protein, which can modify the VSMC phenotype to 
limit plaque growth (Feil, Hofmann, & Feil, 2004). This is important 
functional role in vascular remodeling. Ang-(1-7) can enhance the protein 
expression of SM22 α in artery media of ApoE-KO mice (Yang et al., 2013). 
Previous studies showed that, Ang II activated the ERK, JNK and p38MAPK 
signaling pathway in VSMC (Eguchi et al., 2001). These MAPKs can 
regulate the inflammation, proliferation, differentiation, apoptosis and 
survival processes via inducing the expression of inflammatory factors. In 
the study of Ang-(1-7) agonist, AVE0991 decreased the Ang II-induced 
VSMC proliferation, and it also significantly decreased the ROS and p38 
MAPK phosphorylation level. But these results were not observed by the 
primary treated with A779, an antagonist of Ang-(1-7) (Sheng-Long et al., 
2012). The animal experimental results show that Ang II caused loss of 
smooth muscle cells, elastin fragmentation, and presence of adventitial 
inflammation (Rateri et al., 2014)。 
 
Adventitia 
 Atherosclerosis was considered related to adventitial inflammation 
for many decades (Schwartz & Mitchell, 1962). In 1985, Kohchi et 
al.(Kohchi, Takebayashi, Hiroki, & Nobuyoshi, 1985) found significant 
adventitial inflammation of the coronary artery in patients with unstable 
angina. This study demonstrated that adventitial inflammation possibly 
related to macrophage infiltration. Until recent years, the relevance of 
adventitial inflammation and atherosclerosis attracts the focus from 
researchers. Daugherty et al.(Daugherty et al., 2000) observed that 
macrophages accumulated in adventitia of abdominal aortic part in Ang II-
induced mice model. Then, several studies showed that T and B cells also 
aggregated in adventitia (Akhavanpoor et al., 2014). All these results lead to 
increased local expression of cytokines and growth factors, which evoking 
an inflammatory response. Thus, there is one hypothesis is that the 
mechanisms of vascular inflammation started from adventitia inward toward 
the intima. But, the relevance between Ang-(1-7)/Mas axis is still unclear. 
European Scientific Journal November 2015 edition vol.11, No.33 ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
11 
 
Figure 2 
 
 Activation of the Ang-(1-7)/Mas receptor axis improves vascular 
inflammation. But the prevention mechanism of Ang-(1-7)/Mas receptor axis 
in adventitia is still unknown. EC, endothelial cells; VSMC, vascular smooth 
muscle cells; Ad, adventitia. 
 
Conclusion and perspectives 
 There are two pathways in RAS, ACE/Ang II/AT1R axis and 
ACE2/Ang-(1-7)/Mas axis. Both of them act an important role in all the 
stages of atherosclerosis, hypertension and aneurysm. Ang II, as a key factor 
in RAS, induces hypertension and increases the atherosclerosis incidence. 
And Ang-(1-7) shows a prevention mechanism in the development of 
atherosclerosis, including vasodilation, anti-proliferation, anti-inflammation 
and anti-fibrosis. In addition to this, the expression of many inflammatory 
factors will be reduced by the activated ACE2/Ang-(1-7)/Mas axis in order 
to improve the development of atherosclerosis. However, Ang-(1-7) is not 
enough to be a commercial product as it’s easy to be degraded by the 
proteases. Therefore, many agonists appeared in the view of researchers for 
clinical application. For instance, CGEN-856S and AVE0991 can activate 
Ang-(1-7)/Mas axis. Both A779 and D-Pro-angiotensin-(1-7) are the 
antagonists of Ang-(1-7). AR244555 is an inverse agonist of Mas receptor. 
All of them have made contributions in the research of RAS. 
 In summary, Ang-(1-7) and its Mas receptors are widely expressed in 
many organs of the human body. It plays a central role in the avoidance of 
atherosclerosis. In recent years, studies in ACE2/Ang-(1-7)/Mas axis have 
made significant progress. Not with standing, there are many questions still 
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unclear. More pathological mechanisms need to be resolved and detected. 
Research in the ACE2/Ang-(1-7)/Mas axis can improve our understanding to 
the pathological process of atherosclerosis. This will provide us a more 
theoretical basis for prevention strategy, treatment method and drug 
development from the molecule level in future.  
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